Showing results (441-450 of 481) with videos related to

Sort By:
Pageof 49
Antimicrobial Resistance and Infection Control|March 29, 2018
Vancomycin-resistant Enterococcus faecium sequence type 796 - rapid international dissemination of a new epidemic cloneAndrew A Mahony, Andrew H Buultjens, Susan A Ballard, et al.
The Journal of Infectious Diseases|May 28, 2014
Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infectionNetanya G Sandler, Xinyan Zhang, Ronald J Bosch, et al.
Infection Control and Hospital Epidemiology|June 11, 2004
Eradication of a large outbreak of a single strain of vanB vancomycin-resistant Enterococcus faecium at a major Australian teaching hospitalKeryn J Christiansen, Patricia A Tibbett, William Beresford, et al.
Open Forum Infectious Diseases|January 29, 2021
Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 VaccineesKarina Oganezova, Elvin J Fontana-Martinez, Jon A Gothing, et al.
Statistics in Medicine|November 20, 1998
Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshopJ M Albert, J P Ioannidis, P Reichelderfer, et al.
The Journal of Infectious Diseases|October 1, 1996
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 TeamS L Welles, J B Jackson, B Yen-Lieberman, et al.
Journal of Clinical Microbiology|May 26, 2018
Comparison of Detection Limits of Fourth- and Fifth-Generation Combination HIV Antigen-Antibody, p24 Antigen, and Viral Load Assays on Diverse HIV IsolatesMars Stone, John Bainbridge, Ana M Sanchez, et al.
Plos One|September 6, 2017
Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agentAbiodun D Ogunniyi, Manouchehr Khazandi, Andrew J Stevens, et al.
Science Translational Medicine|December 23, 2021
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virusWilliam A Fischer, Joseph J Eron, Wayne Holman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 6, 2023
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 TrialNikolaus Jilg, Kara W Chew, Mark J Giganti, et al.
Pageof 49